<!doctype html><html lang=en><head><meta charset=utf-8><meta name=description content="Most common form of breast cancer in the UK - around 1 in 8 lifetime risk for women (1% of UK cases are male)"><meta property="og:title" content="Breast carcinoma"><meta property="og:description" content="Most common form of breast cancer in the UK - around 1 in 8 lifetime risk for women (1% of UK cases are male)"><meta property="og:type" content="website"><meta property="og:image" content="https://notes.nosos.co.uk/icon.png"><meta property="og:url" content="https://notes.nosos.co.uk/Breast-carcinoma/"><meta property="og:width" content="200"><meta property="og:height" content="200"><meta name=twitter:card content="summary"><meta name=twitter:title content="Breast carcinoma"><meta name=twitter:description content="Most common form of breast cancer in the UK - around 1 in 8 lifetime risk for women (1% of UK cases are male)"><meta name=twitter:image content="https://notes.nosos.co.uk/icon.png"><title>Breast carcinoma</title><meta name=viewport content="width=device-width,initial-scale=1"><link rel="shortcut icon" type=image/png href=https://notes.nosos.co.uk//icon.png media="(prefers-color-scheme: dark"><link rel="shortcut icon" type=image/png href=https://notes.nosos.co.uk//icon.png-dark.png media="(prefers-color-scheme: light"><link href=https://notes.nosos.co.uk/styles.61b7f083b0774b0c42e780c0bc55ee73.min.css rel=stylesheet><link href=https://notes.nosos.co.uk/styles/_light_syntax.86a48a52faebeaaf42158b72922b1c90.min.css rel=stylesheet id=theme-link><script src=https://notes.nosos.co.uk/js/darkmode.660ec90bf737ee058bec1d99e0222946.min.js></script>
<script src=https://notes.nosos.co.uk/js/util.00639692264b21bc3ee219733d38a8be.min.js></script>
<link rel=preload href=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/katex.min.css as=style onload='this.onload=null,this.rel="stylesheet"' integrity=sha384-R4558gYOUz8mP9YWpZJjofhk+zx0AS11p36HnD2ZKj/6JR5z27gSSULCNHIRReVs crossorigin=anonymous><script defer src=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/katex.min.js integrity=sha384-z1fJDqw8ZApjGO3/unPWUPsIymfsJmyrDVWC8Tv/a1HeOtGmkwNd/7xUS0Xcnvsx crossorigin=anonymous></script>
<script defer src=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/contrib/auto-render.min.js integrity=sha384-+XBljXPPiv+OzfbB3cVmLHf4hdUFHlWNZN5spNQ7rmHTXpd7WvJum6fIACpNNfIR crossorigin=anonymous></script>
<script defer src=https://cdn.jsdelivr.net/npm/katex@0.16.2/dist/contrib/copy-tex.min.js integrity=sha384-ww/583aHhxWkz5DEVn6OKtNiIaLi2iBRNZXfJRiY1Ai7tnJ9UXpEsyvOITVpTl4A crossorigin=anonymous></script>
<script src=https://cdn.jsdelivr.net/npm/@floating-ui/core@1.2.1></script>
<script src=https://cdn.jsdelivr.net/npm/@floating-ui/dom@1.2.1></script>
<script defer src=https://notes.nosos.co.uk/js/popover.aa9bc99c7c38d3ae9538f218f1416adb.min.js></script>
<script defer src=https://notes.nosos.co.uk/js/code-title.ce4a43f09239a9efb48fee342e8ef2df.min.js></script>
<script defer src=https://notes.nosos.co.uk/js/clipboard.2913da76d3cb21c5deaa4bae7da38c9f.min.js></script>
<script defer src=https://notes.nosos.co.uk/js/callouts.7723cac461d613d118ee8bb8216b9838.min.js></script>
<script>const SEARCH_ENABLED=!1,LATEX_ENABLED=!0,PRODUCTION=!0,BASE_URL="https://notes.nosos.co.uk/",fetchData=Promise.all([fetch("https://notes.nosos.co.uk/indices/linkIndex.613ba991f100c4003eccf0797252f0ac.min.json").then(e=>e.json()).then(e=>({index:e.index,links:e.links})),fetch("https://notes.nosos.co.uk/indices/contentIndex.758ec0181eee01b4e6a777339c3e0d03.min.json").then(e=>e.json())]).then(([{index:e,links:t},n])=>({index:e,links:t,content:n})),render=()=>{const e=new URL(BASE_URL),t=e.pathname,n=window.location.pathname,s=t==n;addCopyButtons(),addTitleToCodeBlocks(),addCollapsibleCallouts(),initPopover("https://notes.nosos.co.uk",!0);const o=document.getElementById("footer");if(o){const e=document.getElementById("graph-container");if(!e)return requestAnimationFrame(render);e.textContent="";const t=s&&!0;drawGraph("https://notes.nosos.co.uk",t,[{"/moc":"#4388cc"}],t?{centerForce:.3,depth:-1,enableDrag:!0,enableLegend:!1,enableZoom:!0,fontSize:.2,linkDistance:30,opacityScale:1,repelForce:.5,scale:.9}:{centerForce:1,depth:1,enableDrag:!0,enableLegend:!1,enableZoom:!0,fontSize:.6,linkDistance:1,opacityScale:3,repelForce:2,scale:1.2})}var i=document.getElementsByClassName("mermaid");i.length>0&&import("https://unpkg.com/mermaid@9/dist/mermaid.esm.min.mjs").then(e=>{e.default.init()});function a(n){const e=n.target,t=e.className.split(" "),s=t.includes("broken"),o=t.includes("internal-link");plausible("Link Click",{props:{href:e.href,broken:s,internal:o,graph:!1}})}const r=document.querySelectorAll("a");for(link of r)link.className.includes("root-title")&&link.addEventListener("click",a,{once:!0})},init=(e=document)=>{addCopyButtons(),addTitleToCodeBlocks(),renderMathInElement(e.body,{delimiters:[{left:"$$",right:"$$",display:!0},{left:"$",right:"$",display:!1}],macros:{'’':"'"},throwOnError:!1})}</script><script type=module>
    import { attachSPARouting } from "https:\/\/notes.nosos.co.uk\/js\/router.d6fe6bd821db9ea97f9aeefae814d8e7.min.js"
    attachSPARouting(init, render)
  </script><script defer data-domain=notes.nosos.co.uk src=https://plausible.io/js/script.js></script>
<script>window.plausible=window.plausible||function(){(window.plausible.q=window.plausible.q||[]).push(arguments)}</script></head><body><div id=search-container><div id=search-space><input autocomplete=off id=search-bar name=search type=text aria-label=Search placeholder="Search for something..."><div id=results-container></div></div></div><script src=https://cdn.jsdelivr.net/npm/flexsearch@0.7.21/dist/flexsearch.bundle.js integrity="sha256-i3A0NZGkhsKjVMzFxv3ksk0DZh3aXqu0l49Bbh0MdjE=" crossorigin=anonymous defer></script>
<script defer src=https://notes.nosos.co.uk/js/full-text-search.e6e2e0c213187ca0c703d6e2c7a77fcd.min.js></script><div class=singlePage><header><h1 id=page-title><a class=root-title href=https://notes.nosos.co.uk/>Home</a></h1><div class=spacer></div><div id=search-icon><p>Search</p><svg tabindex="0" aria-labelledby="title desc" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 19.9 19.7"><title id="title">Search Icon</title><desc id="desc">Icon to open search</desc><g class="search-path" fill="none"><path stroke-linecap="square" d="M18.5 18.3l-5.4-5.4"/><circle cx="8" cy="8" r="7"/></g></svg></div><div class=darkmode><input class=toggle id=darkmode-toggle type=checkbox tabindex=-1>
<label id=toggle-label-light for=darkmode-toggle tabindex=-1><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" id="dayIcon" viewBox="0 0 35 35" style="enable-background:new 0 0 35 35"><title>Light Mode</title><path d="M6 17.5C6 16.672 5.328 16 4.5 16h-3C.672 16 0 16.672.0 17.5S.672 19 1.5 19h3C5.328 19 6 18.328 6 17.5zM7.5 26c-.414.0-.789.168-1.061.439l-2 2C4.168 28.711 4 29.086 4 29.5 4 30.328 4.671 31 5.5 31c.414.0.789-.168 1.06-.44l2-2C8.832 28.289 9 27.914 9 27.5 9 26.672 8.329 26 7.5 26zm10-20C18.329 6 19 5.328 19 4.5v-3C19 .672 18.329.0 17.5.0S16 .672 16 1.5v3C16 5.328 16.671 6 17.5 6zm10 3c.414.0.789-.168 1.06-.439l2-2C30.832 6.289 31 5.914 31 5.5 31 4.672 30.329 4 29.5 4c-.414.0-.789.168-1.061.44l-2 2C26.168 6.711 26 7.086 26 7.5 26 8.328 26.671 9 27.5 9zM6.439 8.561C6.711 8.832 7.086 9 7.5 9 8.328 9 9 8.328 9 7.5c0-.414-.168-.789-.439-1.061l-2-2C6.289 4.168 5.914 4 5.5 4 4.672 4 4 4.672 4 5.5c0 .414.168.789.439 1.06l2 2.001zM33.5 16h-3c-.828.0-1.5.672-1.5 1.5s.672 1.5 1.5 1.5h3c.828.0 1.5-.672 1.5-1.5S34.328 16 33.5 16zM28.561 26.439C28.289 26.168 27.914 26 27.5 26c-.828.0-1.5.672-1.5 1.5.0.414.168.789.439 1.06l2 2C28.711 30.832 29.086 31 29.5 31c.828.0 1.5-.672 1.5-1.5.0-.414-.168-.789-.439-1.061l-2-2zM17.5 29c-.829.0-1.5.672-1.5 1.5v3c0 .828.671 1.5 1.5 1.5s1.5-.672 1.5-1.5v-3C19 29.672 18.329 29 17.5 29zm0-22C11.71 7 7 11.71 7 17.5S11.71 28 17.5 28 28 23.29 28 17.5 23.29 7 17.5 7zm0 18c-4.136.0-7.5-3.364-7.5-7.5s3.364-7.5 7.5-7.5 7.5 3.364 7.5 7.5S21.636 25 17.5 25z"/></svg></label><label id=toggle-label-dark for=darkmode-toggle tabindex=-1><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" id="nightIcon" viewBox="0 0 100 100" style="enable-background='new 0 0 100 100'"><title>Dark Mode</title><path d="M96.76 66.458c-.853-.852-2.15-1.064-3.23-.534-6.063 2.991-12.858 4.571-19.655 4.571C62.022 70.495 50.88 65.88 42.5 57.5 29.043 44.043 25.658 23.536 34.076 6.47c.532-1.08.318-2.379-.534-3.23-.851-.852-2.15-1.064-3.23-.534-4.918 2.427-9.375 5.619-13.246 9.491-9.447 9.447-14.65 22.008-14.65 35.369.0 13.36 5.203 25.921 14.65 35.368s22.008 14.65 35.368 14.65c13.361.0 25.921-5.203 35.369-14.65 3.872-3.871 7.064-8.328 9.491-13.246C97.826 68.608 97.611 67.309 96.76 66.458z"/></svg></label></div></header><article><h1>Breast carcinoma</h1><p class=meta>Last updated
Feb 22, 2024
<a href=https://github.com/shaggy2922/quartz/tree/hugo/content/Breast%20carcinoma.md rel=noopener>Edit Source</a></p><ul class=tags><li><a href=https://notes.nosos.co.uk/tags/Gynecological/>Gynecological</a></li><li><a href=https://notes.nosos.co.uk/tags/Oncology/>Oncology</a></li><li><a href=https://notes.nosos.co.uk/tags/Surgery/>Surgery</a></li></ul><aside class=mainTOC><details><summary>Table of Contents</summary><nav id=TableOfContents><ol><li><a href=#types>Types</a></li><li><a href=#causesfactors>Causes/Factors</a></li><li><a href=#presentation>Presentation</a></li><li><a href=#investigations>Investigations</a><ol><li><a href=#high-risk-patients>High risk patients</a></li></ol></li><li><a href=#management>Management</a></li><li><a href=#complicationsred-flags>Complications/red Flags</a></li></ol></nav></details></aside><p>Most common form of breast cancer in the UK - around 1 in 8 lifetime risk for women (1% of UK cases are male)</p><a href=#types><h2 id=types><span class=hanchor arialabel=Anchor># </span>Types</h2></a><p><strong>Non-invasive ductal carcinoma <em>in situ</em> (DCIS)</strong></p><ul><li>Pre-malignant cancer of epithelial cells of breast ducts</li><li>Localised to a single area</li><li>Often picked up by mammogram screening</li><li>Potential to spread locally over years</li><li>30% become invasive</li><li>Good prognosis if excised and adjuvant treatment</li></ul><p><strong>Lobular carcinoma <em>in situ</em> (LCIS)</strong></p><ul><li>Pre-malignant typically in pre-menopausal women</li><li>Rarer and tends to be multifocal</li><li>Increased risk of invasive breast cancer in the future (~30%)</li><li>Often managed conservatively with monitoring (6 monthly exam and yearly mammogram)</li></ul><p><strong>Invasive ductal carcinoma - NST</strong></p><ul><li>Most common invasive carcinoma (80%)</li><li>NST - means no specific type and its not specifically classified (eg medullary or mucinous)</li><li>Originate in cells from the breast ducts</li><li>Can be seen on mammograms</li></ul><p><strong>Invasive lobular carcinomas</strong></p><ul><li>Around 15% of invasive breast cancers</li><li>Originate in cells from the breast lobules</li><li>Not always visible on mammograms</li></ul><p><strong>Inflammatory breast cancer</strong></p><ul><li>1-3% of carcinomas</li><li>Presents similarly to a breast abscess or mastitis</li><li>Swollen, warm, tender breast with pitting skin (peau d&rsquo;orange)</li><li>Does not respond to antibiotics</li><li>Worse prognosis than other breast cancers</li></ul><p><strong>Paget’s Disease of the Nipple</strong></p><ul><li>Looks like eczema of the nipple/areolar</li><li>Erythematous, scaly rash</li><li>Indicates breast cancer involving the nipple</li><li>May represent DCIS or invasive breast cancer</li><li>Requires biopsy, staging and treatment, as with any other invasive breast cancer</li></ul><p><strong>Rarer Types of Breast Cancer</strong></p><ul><li>Medullary breast cancer</li><li>Mucinous breast cancer</li><li>Tubular breast cancer</li><li>Multiple others</li></ul><a href=#causesfactors><h2 id=causesfactors><span class=hanchor arialabel=Anchor># </span>Causes/Factors</h2></a><ul><li>Family history - first degree (BRCA1/2 gene)<ul><li>BRCA1 gene on chromosome 17<ul><li>Around 70% will develop breast cancer by 80</li><li>Around 50% will develop ovarian cancer</li><li>Also increased risk of bowel and prostate</li></ul></li><li>BRCA2 gene on chromosome 13<ul><li>Around 60% will develop breast cancer by aged 80</li><li>Around 20% will develop ovarian cancer</li></ul></li></ul></li><li>Increased oestrogen exposure (earlier onset of periods and later menopause; nulliparity; 1st pregnancy 30>yrs old)</li><li>More dense breast tissue - more glandular tissue</li><li>Obesity</li><li>Smoking</li></ul><a href=#presentation><h2 id=presentation><span class=hanchor arialabel=Anchor># </span>Presentation</h2></a><ul><li>Lumps that are hard, irregular, painless or fixed in place</li><li>Lumps may be tethered to the skin or the chest wall</li><li>Nipple retraction</li><li>Skin dimpling or oedema (peau d’orange)</li><li>Lymphadenopathy, particularly in the axilla</li></ul><blockquote class=todo-callout><p>Referral Criteria
Two week wait referral for:</p><ul><li>Unexplained breast lump in patients aged 30 or above</li><li>Unilateral nipple changes in patients aged over 50 or above</li><li>Unexplained lump in the axilla in patients aged 30 or above</li><li>Skin changes suggestive of breast cancer</li></ul></blockquote><a href=#investigations><h2 id=investigations><span class=hanchor arialabel=Anchor># </span>Investigations</h2></a><blockquote class=abstract-callout><p>Triple assessment</p><ul><li><strong><em>Clinical assessment</em></strong> (history and examination)</li><li><strong><em>Imaging</em></strong> (ultrasound or mammography)</li><li><strong><em>Biopsy</em></strong> (fine needle aspiration or core biopsy)</li></ul></blockquote><ul><li><p><strong><em>Ultrasound scans</em></strong> are typically used to assess lumps in younger women - distinguish solid lumps from cystic fluid</p></li><li><p><strong><em>Mammograms</em></strong> are generally more effective in older women - can find calcifications</p></li><li><p><em><strong>MRI</strong></em> for screening women in higher risk groups or to further assess the size and features of a tumour</p></li><li><p><strong><em>Sentinel lymph node biopsy</em></strong> may be used during breast cancer surgery where the initial ultrasound does not show any abnormal nodes.</p><ul><li>Contrast in injected into the tumour area and travels through the lymphatics to the first lymph node - sentinel.</li></ul></li><li><p>Cancer histology - may have receptors:</p><ul><li>Oestrogen receptors (ER)</li><li>Progesterone receptors (PR)</li><li>Human epidermal growth factor (HER2)
<strong><em>Triple-negative breast cancer</em></strong> is where the breast cancer cells do not express any of these three receptors. This carries a worse prognosis, as it limits the treatment options for targeting the cancer.</li></ul></li></ul><blockquote class=success-callout><p>Breast cancer screening</p><p>The NHS breast cancer screening program offers a <strong><em>mammogram</em></strong> every <strong>3 years</strong> to women aged <strong>50 – 70 years</strong>.</p><p>Screening aims to detect breast cancer early, which improves outcomes. Roughly 1 in 100 women are diagnosed with breast cancer after going for a mammogram.</p></blockquote><a href=#high-risk-patients><h3 id=high-risk-patients><span class=hanchor arialabel=Anchor># </span>High risk patients</h3></a><p>There are different recommendations for screening patients with a higher risk.</p><ul><li>Genetic counselling</li><li>Annual mammogram</li><li>Chemoprevention<ul><li>Tamoxifen (ER modulator) if premenopausal</li><li>Anastrozole (prevents conversion of androgens to oestrogen) if post (except with severe osteoporosis)</li></ul></li></ul><a href=#management><h2 id=management><span class=hanchor arialabel=Anchor># </span>Management</h2></a><p>TNM staging:
<img src="/z_attachments/Pasted image 20240220153923.png" width=550></p><p>All patients are discussed with the <strong><em>multidisciplinary team</em></strong> (<strong><em>MDT</em></strong>) for treatment planning</p><p><strong>Surgery</strong></p><ul><li>Tumour removal</li><li>Axillary clearance</li><li>Reconstructive - immediate or delayed. Can be partial or reduce and reshape both breasts to match</li></ul><p><strong>Radiotherapy</strong></p><p><strong>Chemotherapy</strong></p><ul><li><strong><em>Neoadjuvant therapy</em></strong> – intended to shrink the tumour before surgery</li><li><strong><em>Adjuvant chemotherapy</em></strong> – given after surgery to reduce recurrence</li><li><strong><em>Treatment</em></strong> of metastatic or recurrent breast cancer</li></ul><p><strong>Drug treatment</strong></p><ul><li>Tamoxifen for premenopausal</li><li>Aromatase inhibitors for post</li></ul><p>ER positive</p><ul><li>Fulvestrant (selective ER down regulator )</li><li>GnRH (Gonadotropin releasing hormone)</li></ul><p>HER2 positive</p><ul><li>Herceptin (<em>trastuzumab</em>) - monoclonal antibody targets HER2 receptor. Can also affect heart function so initial heart monitoring is required</li><li>Perjeta (<em>pertuzumab</em>) for HER2 receptor can be used in combination with herceptin</li><li>Nerlynx (<em>neratinib</em>) - tryosine kinase inhibitor reducing the growth of breast cancers</li></ul><hr><a href=#complicationsred-flags><h2 id=complicationsred-flags><span class=hanchor arialabel=Anchor># </span>Complications/red Flags</h2></a><p>Metastasis</p><ul><li><strong>L</strong>ungs
- <strong>L</strong>iver</li><li><strong>B</strong>ones</li><li><strong>B</strong>rain</li></ul><p>Chronic lymphoedema = impaired drainage in that area</p><blockquote class=warning-callout><p>Cannulas and bloods</p><p>Avoid taking blood or putting a cannula in the arm on the side of previous breast cancer surgery. Higher risk of complications and infections due to the impaired lymphatic drainage on that side</p></blockquote></article><hr><div class=page-end id=footer><div class=backlinks-container><h3>Backlinks</h3><ul class=backlinks><li><a href=/Breast-lumps/ data-ctx="Breast carcinoma" data-src=/Breast-lumps class=internal-link>Breast lumps</a></li></ul></div><div><script src=https://cdn.jsdelivr.net/npm/d3@6.7.0/dist/d3.min.js integrity="sha256-+7jaYCp29O1JusNWHaYtgUn6EhuP0VaFuswhNV06MyI=" crossorigin=anonymous></script><h3>Interactive Graph</h3><div id=graph-container></div><style>:root{--g-node:var(--secondary);--g-node-active:var(--primary);--g-node-inactive:var(--visited);--g-link:var(--outlinegray);--g-link-active:#5a7282}</style><script src=https://notes.nosos.co.uk/js/graph.6579af7b10c818dbd2ca038702db0224.js></script></div></div><div id=contact_buttons><footer><p>Evan McNab © 2024</p><ul><li><a href=https://notes.nosos.co.uk/>Home</a></li><li><a href=https://www.nosos.co.uk/>Nosos</a></li><li><a href=https://notes.nosos.co.uk/tags/>Tags</a></li></ul></footer></div></div></body></html>